THYROID ASSOCIATED OPHTHALMOPATHIES
Clinical trials for THYROID ASSOCIATED OPHTHALMOPATHIES explained in plain language.
Never miss a new study
Get alerted when new THYROID ASSOCIATED OPHTHALMOPATHIES trials appear
Sign up with your email to follow new studies for THYROID ASSOCIATED OPHTHALMOPATHIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody injection could ease bulging eyes in thyroid disease
Disease control Recruiting nowThis Phase 3 trial tests MHB018A, an antibody injection, against placebo in 108 people with active moderate-to-severe thyroid eye disease. Participants receive six injections over 24 weeks. The main goal is to see if the drug reduces eye bulging by at least 2 mm without worsening…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New antibody IBI311 takes on steroids in Head-to-Head trial for thyroid eye disease
Disease control Recruiting nowThis study tests whether a new drug called IBI311 works better than standard steroid therapy for people with active moderate to severe thyroid eye disease. 64 participants will receive either IBI311 or steroids, and researchers will measure improvements in eye bulging, inflammati…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:13 UTC
-
New antibody drug aims to ease double vision and bulging eyes in thyroid disease
Disease control Recruiting nowThis study tests a drug called IBI311 in 50 people with inactive moderate-to-severe thyroid eye disease, a condition that can cause bulging eyes and double vision. IBI311 is an antibody that blocks a protein involved in the disease. The goal is to see if it improves eye symptoms …
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:04 UTC
-
New combo therapy aims to tame thyroid eye disease
Disease control Recruiting nowThis study tests a two-step treatment for people with moderate-to-severe thyroid eye disease (TAO) that is still active. First, patients receive high-dose steroids, then a newer drug called tetuzumab (IBI311) that blocks a growth factor receptor. The goal is to reduce bulging eye…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Phase: PHASE4 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jun 26, 2026 12:42 UTC
-
Can eye tracking reveal hidden effects of thyroid eye disease?
Knowledge-focused Recruiting nowThis study uses a non-invasive eye tracker to measure how well people with Thyroid-Associated Ophthalmopathy (TAO) can move their eyes and pay attention to faces. Researchers will compare 100 participants, including patients and healthy volunteers, to see if the disease causes me…
Matched conditions: THYROID ASSOCIATED OPHTHALMOPATHIES
Sponsor: Shanghai Changzheng Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC